细胞因子诱导的杀伤细胞介导的通路在结直肠癌治疗中的作用。
Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer.
机构信息
Students' Research Committee, Alborz University of Medical Sciences, Alborz, Iran.
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Alborz, Iran.
出版信息
Cell Commun Signal. 2022 Mar 28;20(1):41. doi: 10.1186/s12964-022-00836-0.
Cytokine-induced killer (CIK) cell therapy is a type of adoptive immunotherapy that due to its high proliferation rate and anti-tumor characteristics, is being investigated to treat various solid tumors. Since advanced colorectal cancer (CRC) has high mortality and poor survival rates, and the efficacy of chemotherapy and radiotherapy is limited in treatment, the application of CIK cell therapy in CRC has been evaluated in numerous studies. This review aims to summarize the clinical studies that investigated the safety and clinical efficacy of CIK cell therapy in CRC. Therefore, 1,969 enrolled CRC patients in the clinical trials, of which 842 patients received CIK cells in combination with chemotherapy with or without dendritic cell (DC) infusions, were included in the present review. Furthermore, the signaling pathways involved in CIK cell therapy and novel methods for improving migration abilities are discussed. Video abstract.
细胞因子诱导的杀伤（CIK）细胞治疗是一种过继免疫疗法，由于其高增殖率和抗肿瘤特性，正在被研究用于治疗各种实体瘤。由于晚期结直肠癌（CRC）死亡率高、生存率低，且化疗和放疗的疗效有限，因此已经在大量研究中评估了 CIK 细胞治疗在 CRC 中的应用。本综述旨在总结 CIK 细胞治疗 CRC 的安全性和临床疗效的临床研究。因此，在临床试验中纳入了 1969 名 CRC 患者，其中 842 名患者接受了 CIK 细胞联合化疗，有或没有树突状细胞（DC）输注，本综述纳入了这部分患者。此外，还讨论了 CIK 细胞治疗涉及的信号通路以及提高迁移能力的新方法。视频摘要。
Zotero 插件